相关实验视频

Updated: Jun 29, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

在NSCLC中,DRD1抑制细胞增殖,并减少EGFR激活和PD-L1表达

Christopher E Grant¹, Amy L Flis¹, Leila Toulabi¹

¹Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Molecular oncology

|April 4, 2024

概括

通过高甲基化损失多巴胺受体D1 (DRD1) 在非小细胞肺癌 (NSCLC) 中很常见,并且与更差的生存率有关. 通过抑制EGFR和PD-L1通路,DRD1抑制瘤生长,这表明DRD1甲基化作为预后生物标志物.

科学领域:

神经科学是一个神经科学.
在瘤学瘤学.
分子生物学分子生物学

背景情况:

多巴胺 (DA) 信号影响神经和生理过程,包括癌症的进展.
多巴胺受体D1 (DRD1) 途径在固体瘤中的作用取决于组织和细胞的环境.
了解DRD1在非小细胞肺癌 (NSCLC) 中的特定功能对于向治疗至关重要.

研究的目的:

研究DRD1在NSCLC中的表达和甲基化状态.
确定DRD1对NSCLC细胞增殖和瘤生长的功能影响.
阐明DRD1,表皮生长因子受体 (EGFR) 途径和编程细胞死亡11 (PD-L1) 之间的机械联系.

主要方法:

在NSCLC样本中对DRD1表达和甲基化分析进行RNA测序 (RNAseq) 和逆转录聚合酶链反应 (RT-PCR).
使用癌症基因组图谱 (TCGA) 数据集的验证.
实验室和体内功能测试用于扩散和瘤生长,以及转录组和基因组分析.

主要成果:

DRD1在正常的肺组织中得到表达,但由于促进物高甲基化,其表达在NSCLC中经常丢失.
失去DRD1表达与患者存活率降低和瘤进展增加有关.
通过抑制EGFR/ERK1/2激活,DRD1抑制NSCLC的增殖,并调节PD-L1的表达.

结论:

在NSCLC中,DRD1作为疾病进展的负调节剂.
DRD1促进剂高甲基化作为NSCLC患者预后不佳的潜在生物标志物.
向DA通路组件可能会增强基于EGFR和PD-L1的癌症疗法的疗效.

关键词:

DRD1 DRD1 DRD1 DRD1 DRD1 DRD1 DRD1 DRD1 欧洲农业基金会 (EGFR) 是一个基金.在PD-L1中.多巴胺是多巴胺的一种.非小细胞肺癌的肺癌.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.